Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Shares of NovaBay Pharmaceuticals Inc. (NBY) are surging over 42% in pre-market today, after the company announced testing results from an independent third-party laboratory confirming that Avenova, NovaBay's proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.


RTTNews | Jul 13, 2020 09:05AM EDT

09:04 Monday, July 13, 2020 (RTTNews.com) - Shares of NovaBay Pharmaceuticals Inc. (NBY) are surging over 42% in pre-market today, after the company announced testing results from an independent third-party laboratory confirming that Avenova, NovaBay's proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.

As previously announced, NovaBay continues to work with the U.S. FDA on the Emergency Use Authorization or EUA for the fluorecare SARS-CoV-2 IgG & IgM Antibody Combined Test Kit. The FDA has not provided a timeline for completion of the review, the company added.

The stock has been trading in the range of $0.24 - $1.85 for the past one year, and closed Friday's trade at $1.13, down 2 cents or 1.74%. NBY is currently trading at $1.62, up 48 cents or 42.11% in the pre-market session.

Read the original article on RTTNews ( https://www.rttnews.com/3110511/stock-alert-novabay-pharma-shares-soar-42-in-early-trade.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC